108 related articles for article (PubMed ID: 19424623)
1. Efficacy of triple therapies including ionising radiation, agonistic TRAIL antibodies and cisplatin.
Niyazi M; Marini P; Daniel PT; Humphreys R; Jendrossek V; Belka C
Oncol Rep; 2009 Jun; 21(6):1455-60. PubMed ID: 19424623
[TBL] [Abstract][Full Text] [Related]
2. Efficacy of a triple treatment with irradiation, agonistic TRAIL receptor antibodies and EGFR blockade.
Niyazi M; Marini P; Daniel PT; Humphreys R; Jendrossek V; Belka C
Strahlenther Onkol; 2009 Jan; 185(1):8-18. PubMed ID: 19224142
[TBL] [Abstract][Full Text] [Related]
3. Combined treatment of colorectal tumours with agonistic TRAIL receptor antibodies HGS-ETR1 and HGS-ETR2 and radiotherapy: enhanced effects in vitro and dose-dependent growth delay in vivo.
Marini P; Denzinger S; Schiller D; Kauder S; Welz S; Humphreys R; Daniel PT; Jendrossek V; Budach W; Belka C
Oncogene; 2006 Aug; 25(37):5145-54. PubMed ID: 16636678
[TBL] [Abstract][Full Text] [Related]
4. Activity of selective fully human agonistic antibodies to the TRAIL death receptors TRAIL-R1 and TRAIL-R2 in primary and cultured lymphoma cells: induction of apoptosis and enhancement of doxorubicin- and bortezomib-induced cell death.
Georgakis GV; Li Y; Humphreys R; Andreeff M; O'Brien S; Younes M; Carbone A; Albert V; Younes A
Br J Haematol; 2005 Aug; 130(4):501-10. PubMed ID: 16098063
[TBL] [Abstract][Full Text] [Related]
5. Human agonistic TRAIL receptor antibodies Mapatumumab and Lexatumumab induce apoptosis in malignant mesothelioma and act synergistically with cisplatin.
Belyanskaya LL; Marti TM; Hopkins-Donaldson S; Kurtz S; Felley-Bosco E; Stahel RA
Mol Cancer; 2007 Oct; 6():66. PubMed ID: 17953743
[TBL] [Abstract][Full Text] [Related]
6. Novel in vivo imaging shows up-regulation of death receptors by paclitaxel and correlates with enhanced antitumor effects of receptor agonist antibodies.
Gong J; Yang D; Kohanim S; Humphreys R; Broemeling L; Kurzrock R
Mol Cancer Ther; 2006 Dec; 5(12):2991-3000. PubMed ID: 17148761
[TBL] [Abstract][Full Text] [Related]
7. Enhancement of lexatumumab-induced apoptosis in human solid cancer cells by Cisplatin in caspase-dependent manner.
Wu XX; Kakehi Y
Clin Cancer Res; 2009 Mar; 15(6):2039-47. PubMed ID: 19276256
[TBL] [Abstract][Full Text] [Related]
8. The proteasome inhibitor MG132 potentiates TRAIL receptor agonist-induced apoptosis by stabilizing tBid and Bik in human head and neck squamous cell carcinoma cells.
Sung ES; Park KJ; Choi HJ; Kim CH; Kim YS
Exp Cell Res; 2012 Aug; 318(13):1564-76. PubMed ID: 22513214
[TBL] [Abstract][Full Text] [Related]
9. TRAIL-induced apoptosis is preferentially mediated via TRAIL receptor 1 in pancreatic carcinoma cells and profoundly enhanced by XIAP inhibitors.
Stadel D; Mohr A; Ref C; MacFarlane M; Zhou S; Humphreys R; Bachem M; Cohen G; Möller P; Zwacka RM; Debatin KM; Fulda S
Clin Cancer Res; 2010 Dec; 16(23):5734-49. PubMed ID: 20940278
[TBL] [Abstract][Full Text] [Related]
10. TRAIL signals to apoptosis in chronic lymphocytic leukaemia cells primarily through TRAIL-R1 whereas cross-linked agonistic TRAIL-R2 antibodies facilitate signalling via TRAIL-R2.
Natoni A; MacFarlane M; Inoue S; Walewska R; Majid A; Knee D; Stover DR; Dyer MJ; Cohen GM
Br J Haematol; 2007 Nov; 139(4):568-77. PubMed ID: 17922877
[TBL] [Abstract][Full Text] [Related]
11. Functional expression of TRAIL receptors TRAIL-R1 and TRAIL-R2 in esophageal adenocarcinoma.
Younes M; Georgakis GV; Rahmani M; Beer D; Younes A
Eur J Cancer; 2006 Mar; 42(4):542-7. PubMed ID: 16426839
[TBL] [Abstract][Full Text] [Related]
12. HGS-ETR1, a fully human TRAIL-receptor 1 monoclonal antibody, induces cell death in multiple tumour types in vitro and in vivo.
Pukac L; Kanakaraj P; Humphreys R; Alderson R; Bloom M; Sung C; Riccobene T; Johnson R; Fiscella M; Mahoney A; Carrell J; Boyd E; Yao XT; Zhang L; Zhong L; von Kerczek A; Shepard L; Vaughan T; Edwards B; Dobson C; Salcedo T; Albert V
Br J Cancer; 2005 Apr; 92(8):1430-41. PubMed ID: 15846298
[TBL] [Abstract][Full Text] [Related]
13. Synergistic induction of tumor cell apoptosis by death receptor antibody and chemotherapy agent through JNK/p38 and mitochondrial death pathway.
Ohtsuka T; Buchsbaum D; Oliver P; Makhija S; Kimberly R; Zhou T
Oncogene; 2003 Apr; 22(13):2034-44. PubMed ID: 12673208
[TBL] [Abstract][Full Text] [Related]
14. Monoclonal antibody to tumor necrosis factor-related apoptosis-inducing ligand receptor 2 (TRAIL-R2) induces apoptosis in primary renal cell carcinoma cells in vitro and inhibits tumor growth in vivo.
Zeng Y; Wu XX; Fiscella M; Shimada O; Humphreys R; Albert V; Kakehi Y
Int J Oncol; 2006 Feb; 28(2):421-30. PubMed ID: 16391797
[TBL] [Abstract][Full Text] [Related]
15. Apigenin induces apoptosis via tumor necrosis factor receptor- and Bcl-2-mediated pathway and enhances susceptibility of head and neck squamous cell carcinoma to 5-fluorouracil and cisplatin.
Chan LP; Chou TH; Ding HY; Chen PR; Chiang FY; Kuo PL; Liang CH
Biochim Biophys Acta; 2012 Jul; 1820(7):1081-91. PubMed ID: 22554915
[TBL] [Abstract][Full Text] [Related]
16. Irradiation specifically sensitises solid tumour cell lines to TRAIL mediated apoptosis.
Marini P; Schmid A; Jendrossek V; Faltin H; Daniel PT; Budach W; Belka C
BMC Cancer; 2005 Jan; 5():5. PubMed ID: 15651986
[TBL] [Abstract][Full Text] [Related]
17. Requirement of BAX for TRAIL/Apo2L-induced apoptosis of colorectal cancers: synergism with sulindac-mediated inhibition of Bcl-x(L).
Ravi R; Bedi A
Cancer Res; 2002 Mar; 62(6):1583-7. PubMed ID: 11912124
[TBL] [Abstract][Full Text] [Related]
18. Bortezomib sensitizes non-Hodgkin's lymphoma cells to apoptosis induced by antibodies to tumor necrosis factor related apoptosis-inducing ligand (TRAIL) receptors TRAIL-R1 and TRAIL-R2.
Smith MR; Jin F; Joshi I
Clin Cancer Res; 2007 Sep; 13(18 Pt 2):5528s-5534s. PubMed ID: 17875785
[TBL] [Abstract][Full Text] [Related]
19. Methionine Deprivation Induces a Targetable Vulnerability in Triple-Negative Breast Cancer Cells by Enhancing TRAIL Receptor-2 Expression.
Strekalova E; Malin D; Good DM; Cryns VL
Clin Cancer Res; 2015 Jun; 21(12):2780-91. PubMed ID: 25724522
[TBL] [Abstract][Full Text] [Related]
20. Histone deacetylase inhibitors enhance lexatumumab-induced apoptosis via a p21Cip1-dependent decrease in survivin levels.
Nawrocki ST; Carew JS; Douglas L; Cleveland JL; Humphreys R; Houghton JA
Cancer Res; 2007 Jul; 67(14):6987-94. PubMed ID: 17638911
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
